Everyone seems to be talking about market access these days, but do we actually know what it entails and what the current issues are surrounding it? We caught up with Dr Andy Stainthorpe, Associate Director, National Institute for Health and Clinical Excellence (UK) to get his insight on the following:
- Market access issues that pharmas and biotech face
- How to overcome those issues
- New business models that pharmas can reference
- Benefit of developing niche products
Don’t forget, Andy will be at BioPharma Convention Australasia 2012 to give a keynote address on “How to share risk in health technology assessments”. Join us at the convention to learn from pharma's industry leaders.
For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D